ArteraAI Announces Research Agreement with CorePlus

Date:

Share post:

ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced today a research agreement with CorePlus, a high complexity CLIA-certified clinical and anatomic pathology laboratory headquartered in Carolina, Puerto Rico. The collaboration aims to further validate The ArteraAI Prostate Test in the Hispanic population.

“We are committed to ensuring that our models are trained on datasets that properly represent diverse patient populations,” said Andre Esteva co-founder and CEO of ArteraAI. “Working with CorePlus allows us to enhance our diversity efforts, providing a unique opportunity to conduct comprehensive analytical validation of our models across diverse ethnic groups.”

Prostate cancer is the most commonly diagnosed cancer among Hispanic men in the U.S., comprising more than 1 in 5 of all new cancer diagnoses. Research also shows that 7.2% of Hispanic men who are diagnosed with prostate cancer die from their disease, making it the 4th leading cause of cancer death among this population. In fact, prostate cancer-specific mortality has been shown to be highest in Puerto Rican men, higher than even non-Hispanic blacks.

Also Read: Prime Large Language Models (LLMs)

“We are thrilled to collaborate with ArteraAI to further the advancement and reduction of inequities in prostate cancer diagnosis and treatment,” said Mariano de Socarraz, CEO of CorePlus. “This research agreement provides a strong step forward in increasing understanding of differences and reducing disparities in access to precision diagnostics creating more equitable and personalized care for prostate cancer patients.”

ArteraAI remains committed to incorporating diverse datasets in the training of its AI models, with CorePlus marking the latest endeavor. This collaborative effort extends the work of ArteraAI’s MMAI models, which were deliberately developed using cohorts comprising approximately 20% African Americans— a percentage that mirrors the 16% prevalence of prostate cancer in this specific patient population. The research alliance with CorePlus will provide ArteraAI access to an extensive database of Hispanic patients. CorePlus has applied a prostate-specific artificial intelligence algorithm on more than 10,000 men.

Check Out The New TalkDev Podcast. For more such updates follow us on Google News TalkDev News.

TalkDev Bureau
TalkDev Bureau
The TalkDev Bureau has five well-trained writers and journalists, well versed in B2B enterprise technology industry, and constantly in touch with industry leaders for the latest trends, opinions, and other inputs- to bring you the best and latest in the domain.
spot_img

Related articles

How Does the Kernel Work in the Operating System (OS)

Explore the core of the Operating System (OS) - the Kernel. Unveil its key role in managing system...

Wondershare Unveils Filmora 13.3: Revolutionizing Video Editing with Improved UI, UX, and Advanced Color Grading Features

Wondershare has released Filmora 13.3, the latest flagship video editing software update. This version introduces significant UI and...

Apple Removes WhatsApp and Threads from China App Store on Government Order Citing National Security

Apple has removed Meta Platforms' WhatsApp and Threads from its App Store in China due to national security...

Meta Platforms Unveils Llama 3 AI and Real-Time Image Generator to Rival OpenAI

Meta Platforms has launched early versions of its latest large language model, Llama 3, and an image generator...